ERENUMAB
Information current as at: 1 April 2026
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Aimovig®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Chronic migraine
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- New PBS listing (Standard Re-entry Pathway)
- Comment:
- --
- Submission sponsor:
- NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
- Other PBAC consideration:
Progress Details
-
Submission received for: - November 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 31/07/2024 and close 25/09/2024 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2024
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
PBAC Outcome
Case ID: a932
Page last updated: 31 March 2026